Boceprevir early-access for advanced-fibrosis/cirrhosis in Asia-Pacific hepatitis C virus genotype 1 non-responders/relapsers.

doi:10.3748/wjg.v21.i28.8660

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Boceprevir early-access for advanced-fibrosis/cirrhosis in Asia-Pacific hepatitis C virus genotype 1 non-responders/relapsers.

World journal of gastroenterology - 28 Jul 2015

Sukeepaisarnjaroen Wattana, Pham Tri, Tanwandee Tewesak, Nazareth Saroja, Galhenage Sam, Mollison Lindsay, Totten Leanne, Wigg Alan, Altus Rosalie, Colman Anton, Morales Brenda, Mason Sue, Jones Tracey, Leembruggen Nadine, Fragomelli Vince, Sendall Cheryl, Guan Richard, Sutedja Dede, Tan Soek Siam, Dan Yock Young, Lee Yin Mei, Luman Widjaja, Teo Eng Kiong, Than Yin Min, Piratvisuth Teerha, Lim Seng Gee

Abstract excerpt

AIM: To examined the efficacy and safety of treatment with boceprevir, PEGylated-interferon and ribavirin (PR) in hepatitis C virus genotype 1 (HCVGT1) PR treatment-failures in Asia. METHODS: The Boceprevir Named-Patient Program provided boceprevir to HCVGT1 PR treatment-failures. Participating physicians were invited to contribute data from their patients: baseline characteristics, on-treatment responses,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Asia

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Interferon-alpha

Share to Interferon alpha-2

Share to Liver Cirrhosis

Share to Polyethylene Glycols

Share to Proline

Share to Ribavirin

Share to Treatment Failure

Source

Open in PubMed Open full text

Identifiers

PMID: 26229408
DOI: 10.3748/wjg.v21.i28.8660
PMCID: PMC4515847

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Boceprevir early-access for advanced-fibrosis/cirrhosis in Asia-Pacific hepatitis C virus genotype 1 non-responders/relapsers.PMID 26229408Read ↗

A real life boceprevir use in treatment-experienced HCV genotype 1 patients with advanced fibrosis.Semantic proximity Read ↗

Glecaprevir/pibrentasvir for 8 weeks in treatment-naïve patients with chronic HCV genotypes 1-6 and compensated cirrhosis: The EXPEDITION-8 trial.Semantic proximity Read ↗

Four weeks of off-treatment follow-up is sufficient to determine virologic responses at off-treatment week 12 in patients with hepatitis C virus infection receiving pangenotypic direct-acting antiviralsSemantic proximity Read ↗

Chronic hepatitis C genotype 1 treatment roadmap for resource constrained settings.Semantic proximity Read ↗

Clinical and virological predictors of sustained response with an interferon-based simeprevir regimen for patients with chronic genotype 1 hepatitis C virus infection.Semantic proximity Read ↗

A 2015 roadmap for the management of hepatitis C virus infections in Asia.Semantic proximity Read ↗

Safety profile of boceprevir and telaprevir in chronic hepatitis C: real world experience from HCV-TARGET.Semantic proximity Read ↗

Findings from a large Asian chronic hepatitis C real-life study.Semantic proximity Read ↗

Effectiveness and safety of first-generation protease inhibitors in real-world patients with hepatitis C virus genotype 1 infection in Brazil: a multicenter study.Semantic proximity Read ↗

Multicenter Experience with Boceprevir or Telaprevir to Treat Hepatitis C Recurrence after Liver Transplantation: When Present Becomes Past, What Lessons for Future?Semantic proximity Read ↗

7 BOCEPREVIR IN ADDITION TO STANDARD OF CARE ENHANCED SVR IN HEPATITIS C VIRUS (HCV) GENOTYPE-1 WITH ADVANCED FIBROSIS/CIRRHOSIS: SUBGROUP ANALYSIS OF SPRINT-2 AND RESPOND-2 STUDIESSemantic proximity Read ↗

Triple therapy with boceprevir or telaprevir for prior HCV non-responders.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.